Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > FERRING’s gene therapy: Not what doctors want

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Aug 31, 2023 11:15am

154 Views

Post# 35613820

RE:FERRING’s gene therapy: Not what doctors want

Unlike Ruvidar PDT!

As Dr. Kamat said at the conclusion of our phase 1 trial:

"The clinical data presented by Dr. Kulkarni suggests that the Theralase PDT treatment option may be just what the doctor ordered.”

https://theralase.com/theralase-successfully-completes-phase-ib-non-muscle-invasive-bladder-cancer-clinical-study/

ScienceFirst wrote:
Despite the US jv deal (500M$US + 5-8% of royalties for the US market alone):

https://www.ferring.com/royalty-pharma-and-ferring-pharmaceuticals-enter-into-us-500-million-royalty-agreement-for-new-intravesical-gene-therapy-adstiladrin/

... FERRING's Adstiladrin gene therapy is not the holy-grail. Not what doctors ordered.

https://www.evaluate.com/vantage/articles/analysis/spotlight/renewed-push-early-bladder-cancer

Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.